Gastroenterology

Gastroenterology

Volume 115, Issue 6, December 1998, Pages 1584-1586
Gastroenterology

Editorials
New tool to predict celiac disease on its way to the clinics

https://doi.org/10.1016/S0016-5085(98)70040-XGet rights and content

Abstract

GASTROENTEROLOGY 1998;115:1584-1586

References (24)

  • W Dieterich et al.

    Identification of tissue transglutaminase as the autoantigen of celiac disease

    Nat Med

    (1997)
  • KEA Lundin et al.

    Gliadin-specific, HLA-DQ(α1*0501,β1*0201) restricted T cells isolated from the small intestinal mucosa of celiac disease patients

    J Exp Med

    (1993)
  • Cited by (33)

    • Celiac disease

      2005, Mucosal Immunology, Two-Volume Set
    • Radioimmunoassay to detect antitransglutaminase autoantibodies is the most sensitive and specific screening method for celiac disease

      2001, American Journal of Gastroenterology
      Citation Excerpt :

      Anti-tTGase autoantibodies represent the most recent serological marker proposed for screening of CD (28–30). These autoantibodies are particularly interesting from a speculative point of view because tTGase could catalyze the deamidation of gliadin peptides creating a negative charged residue better recognized by DQ2/DQ8 restricted gut-derived lymphocytes of CD patients (31). At present, two methods are available for tTGase antibody determination: an ELISA method, using guinea pig liver tTGase as antigen (19, 28–30, 32) and a RIA with a human recombinant tTGase (22, 33–35).

    • Human recombinant tissue transglutaminase ELISA: An innovative diagnostic assay for celiac disease

      2000, American Journal of Gastroenterology
      Citation Excerpt :

      In this paper we described the development of an innovative human-based tTG ELISA, which allowed us to identify a total of 12 CD patients missed with the other two currently available noninvasive serological tests (seven patients missed by gp-tTG and five missed by AEA). These results support previously reported concerns regarding the use of nonhuman tTG as an alternative test to the AEA assay (10, 11), and may explain the small but consistent number of patients with CD who test negative by AEA. In our study, two of these patients were affected by IgA deficiency, a condition often associated with CD (17), and the remaining three had low specific anti–h-TG IgA antibodies (13%, 14%, and 20%).

    View all citing articles on Scopus

    Address requests for reprints to: Ludvig M. Sollid, M.D., Institute of Transplantation Immunology, University of Oslo, Rikshospitalet, N-0027 Oslo, Norway. e-mail: [email protected]; fax: (47) 22 20-3693.

    View full text